Traphaco JSCSTC:TRA -0.13%83 EBITDA Margin % is 18.83% as of Mar. 2026, which is 1% above its 10-year median of 18.63. GuruFocus rates STC:TRA with a GF Score™ of 83/100 and a GF Value™ of ₫92,290.93 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, Traphaco JSC ranks better than 62.72% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Traphaco JSC's EBITDA for the
three
months ended in Mar. 2026 was ₫119,137 Mil. Traphaco JSC's Revenue for the
three
months ended in Mar. 2026 was ₫632,847 Mil. Therefore, Traphaco JSC's EBITDA margin for the quarter that ended in Mar. 2026 was 18.83%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Traphaco JSC EBITDA Margin % Related Terms
Traphaco JSC EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Traphaco JSC's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Traphaco JSC's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Traphaco JSC EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Traphaco JSC's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Traphaco JSC's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Traphaco JSC (STC:TRA) has a EBITDA Margin % of 18.83% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Traphaco JSC and its competitors. This is near median its historical median of 18.63. Over the past decade, Traphaco JSC's EBITDA Margin % has ranged from 15.98 to 19.97. According to the industry distribution chart, Traphaco JSC ranks #356 out of 955 companies in the Drug Manufacturers industry, placing it in the top 37.3%.
Is Traphaco JSC's EBITDA Margin % too high?
Traphaco JSC's current EBITDA Margin % of 18.83% is near median its 10-year median of 18.63. Over the past 10 years, this metric has ranged from a low of 15.98 to a high of 19.97. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Traphaco JSC's value of 18.83% is 51.4% above this industry median. Based on the distribution chart, Traphaco JSC ranks #356 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Traphaco JSC has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Traphaco JSC's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Traphaco JSC ranks #356 out of 955 companies for EBITDA Margin %. This puts Traphaco JSC in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Traphaco JSC's value of 18.83% is 51.4% above this benchmark. Historically, Traphaco JSC's own EBITDA Margin % has ranged from 15.98 to 19.97 over the past decade. While the company's 10-year median is 18.63 vs. the industry median of 12.44, Traphaco JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Traphaco JSC's current EBITDA Margin % of 18.83% is 51.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Traphaco JSC and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Traphaco JSC's current EBITDA Margin % is 18.83%, which is near median its own 10-year median of 18.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Traphaco JSC stock overvalued right now?
Based on GuruFocus' analysis, Traphaco JSC (STC:TRA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫92,290.93, compared to a current price of ₫77,900.00 — trading 15.6% below its estimated fair value. The current EBITDA Margin % is 18.83%, which is near median its 10-year median of 18.63 and 51.4% above the Drug Manufacturers industry median of 12.44. Traphaco JSC's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Traphaco JSC (STC:TRA), the current EBITDA Margin % is 18.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Traphaco JSC (STC:TRA) Overvalued in 2026?
Based on GuruFocus' analysis, Traphaco JSC stock appears to be undervalued.
The current stock price of ₫77,900.00 is trading 15.6% below its estimated GF Value™ of ₫92,290.93.
GuruFocus considers Traphaco JSC to be Modestly Undervalued.
Key valuation signals for STC:TRA:
EBITDA Margin %: 18.83% (near median its 10-year median of 18.63)
GF Value™: ₫92,290.93 vs. price of ₫77,900.00 (15.6% below fair value)
Industry Position: 51.4% above the Drug Manufacturers median (#356 of 955)
No single metric tells the full story. See the STC:TRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Traphaco JSC is engaged in the production and trading of pharmaceuticals, chemicals, and medical supplies and equipment. The company's products are used for nourishing the body, the Skeletal system, for hair, for eyes, the Nervous system, the Respiratory system, and Other groups.
83GF Score
Get the complete analysis for STC:TRA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:TRA has been successfully added to your 
